PMID- 28484963
OWN - NLM
STAT- MEDLINE
DCOM- 20180518
LR  - 20220318
IS  - 1550-7416 (Electronic)
IS  - 1550-7416 (Linking)
VI  - 19
IP  - 4
DP  - 2017 Jul
TI  - Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic 
      Stroke.
PG  - 957-972
LID - 10.1208/s12248-017-0091-7 [doi]
AB  - The blood-brain barrier (BBB) is a vital component of the neurovascular unit 
      (NVU) containing tight junctional (TJ) proteins and different ion and nutrient 
      transporters which maintain normal brain physiology. BBB disruption is a major 
      pathological hallmark in the course of ischemic stroke which is regulated by the 
      actions of different factors working at different stages of cerebral ischemia 
      including matrix metalloproteinases (MMPs), inflammatory modulators, vesicular 
      trafficking, oxidative pathways, and junctional-cytoskeletal interactions. These 
      components interact further to disrupt maintenance of both the paracellular and 
      transport barriers of the central nervous system (CNS) to worsen ischemic brain 
      injury and the propensity for hemorrhagic transformation (HT) associated with 
      injury and/or thrombolytic therapy with tissue-type plasminogen activator (tPA). 
      We propose that these complex molecular pathways should be evaluated further so 
      that they could be targeted alone or in combination to protect the BBB during 
      cerebral ischemia. These types of novel interventions should be guided by 
      advanced imaging techniques for better diagnosis of BBB damage which may exert 
      significant therapeutic benefit including the extension of therapeutic window of 
      tPA. This review will focus on the different stages and mechanisms of BBB damage 
      in acute ischemic stroke and novel therapeutic strategies to target those 
      pathways for better therapeutic outcome in stroke.
FAU - Sifat, Ali Ehsan
AU  - Sifat AE
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University 
      Health Sciences Center, 1300 S. Coulter, Amarillo, Texas, 79106, USA.
FAU - Vaidya, Bhuvaneshwar
AU  - Vaidya B
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University 
      Health Sciences Center, 1300 S. Coulter, Amarillo, Texas, 79106, USA.
FAU - Abbruscato, Thomas J
AU  - Abbruscato TJ
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University 
      Health Sciences Center, 1300 S. Coulter, Amarillo, Texas, 79106, USA. 
      Thomas.abbruscato@ttuhsc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170508
PL  - United States
TA  - AAPS J
JT  - The AAPS journal
JID - 101223209
SB  - IM
MH  - Acute Disease
MH  - *Blood-Brain Barrier
MH  - Brain Ischemia/diagnostic imaging/metabolism/*therapy
MH  - Humans
MH  - Stroke/diagnostic imaging/metabolism/*therapy
MH  - Stroke Rehabilitation
MH  - Thrombolytic Therapy
OTO - NOTNLM
OT  - Blood-brain barrier
OT  - Ischemic stroke
OT  - Matrix metalloproteinases
OT  - Tight junction
OT  - Tissue-type plasminogen activator
EDAT- 2017/05/10 06:00
MHDA- 2018/05/19 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/01/14 00:00 [received]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/05/19 06:00 [medline]
PHST- 2017/05/10 06:00 [entrez]
AID - 10.1208/s12248-017-0091-7 [pii]
AID - 10.1208/s12248-017-0091-7 [doi]
PST - ppublish
SO  - AAPS J. 2017 Jul;19(4):957-972. doi: 10.1208/s12248-017-0091-7. Epub 2017 May 8.